Allgens Medical faces CSRC probe over alleged false financial data

The significance here is the regulatory escalation: a CSRC case-filing notice moves the matter from inquiry into formal investigation territory, and Allgens itself has flagged the tail risk that confirmed violations could meet major-violation delisting criteria. That puts the company's disclosure history and internal controls under scrutiny, not just its reported numbers, and matters most for holders exposed to a potential forced-delisting path. The company's assurance that operations and finances remain normal is the standard line and does little to settle the core question. Worth watching is whether the probe stays confined to periodic reports or widens, and how the delisting threshold is ultimately interpreted.